Trump Pharma Tariff Update: 17 Deals Now Signed, But Your Prescription May Still Cost 100% More

# Trump Pharma Tariff Update: 17 Deals Now Signed, But Your Prescription May Still Cost 100% More

> **Quick answer:** As of April 23, 2026, the Trump administration has signed 17 Most Favored Nation (MFN) drug pricing deals covering approximately 86% of the branded pharmaceutical market — including Pfizer, Eli Lilly, Novo Nordisk, AbbVie, and Regeneron. Companies with deals face zero tariff. But the remaining 14% of branded drugs — primarily from mid-size biotech companies — face the full 100% tariff when it takes effect July 31, 2026. Generic drugs remain exempt. Here is how to find out exactly which category your prescription falls into, and what to do before July 31.

The Trump administration's 100% pharmaceutical tariff story has moved fast since the April 2 proclamation — and the picture that has emerged is more complex than the headline implies. If you only read the original coverage, you may be either more worried or less worried than you should be. This update covers what has changed, who is actually protected, and which patients face real exposure in 96 days.

*This article is for informational purposes only and does not replace professional medical advice. Consult a healthcare provider for medical concerns or before making any changes to your prescription medications.*

## What Changed Since April 2: The 17-Deal Landscape

When President Trump signed the Section 232 pharmaceutical tariff proclamation on April 2, 2026, the number of companies with qualifying Most Favored Nation agreements was roughly nine. In the three weeks since, the deal-making pace has accelerated dramatically.